The latest price and purchasing information of brigatinib/brigatinib

Brigatinib/Brigatinib (Brigatinib) is a targeted drug mainly used to treat patients with ALK gene rearrangement-positive non-small cell lung cancer (NSCLC), especially those who have failed or developed resistance to crizotinib (Crizotinib) treatment. This drug effectively prevents the growth and spread of cancer cells by inhibiting ALK activity in tumor cells. Clinical studies of brigatinib have shown that it can not only prolong the progression-free survival of patients, but also improve their quality of life.

In China, brigatinib has been approved by the National Medical Products Administration and is on the market, and has also been included in the medical insurance directory, which provides economic convenience to many patients. When patients choose to purchase brigatinib, they can purchase it through hospitals, pharmacies or professional drug purchasing platforms. Taking 90mg*28 capsules of brigatinib as an example, after medical insurance reimbursement, the actual cost paid by the patient is aboutabout 10,000 yuan, which significantly reduces the economic burden of treatment.

It is worth mentioning that with the development of the global drug market, generic drugs of brigatinib have also begun to be launched in some countries and regions. For example, in places such as Laos and Bangladesh, a variety of generic drugs of brigatinib are available for patients to choose from. The price of these generic drugs is usually much lower than that of the original drugs. Taking 90mg*30 capsules as an example, the price in Laos is about 500 yuan. The specific price varies depending on the manufacturer and sales channel. The emergence of these generic drugs has provided patients with more choices, allowing patients with poor financial conditions to obtain the treatment they need.

Overall, as a new anti-cancer drug, brigatinib’s domestic application and medical insurance coverage have brought hope to many patients with non-small cell lung cancer. At the same time, with the gradual popularization of generic drugs, patients' treatment options and economic burden will be further improved.

Reference materials:https://www.alunbrig.com/